Chinese Drug Firms Race To U.S. With Traditional Medicines
This article was originally published in PharmAsia News
Luye Pharma is the latest Chinese domestic drug manufacturer aiming to launch prescription traditional Chinese medicines in the U.S.
You may also be interested in...
SHANGHAI - After positive Phase II results in the United States last year, Chinese pharmaceutical company Tasly Group has announced an investment of $40 million to build a manufacturing facility and training center in Maryland to help introduce its Compound Danshen Dripping Pills (CDDP) to the American market
Junshi’s oral antiviral shows signs of effectiveness in treating patients with mild COVID-19 symptoms but more data are needed, caution researchers.
2021 saw a record number of novel drug launches and the size of the pipeline topped 20,000 candidates for the first time, new analysis shows, while China came of age as a pharma player.